Figure 1From: Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trialRandomized, placebo-controlled, crossover trial design. Patients were screened for eligibility. Those meeting entry criteria were randomized to one of two treatment sequences: pioglitazone then placebo or placebo then pioglitazone. Patients were assessed every four weeks. Treatment phases were separated by a four-week washout period.Back to article page